NCT02767804 2025-10-14eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsXcovery Holdings, Inc.Phase 3 Active not recruiting290 enrolled 1 FDA
NCT05341583 2024-08-23Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerBetta Pharmaceuticals Co., Ltd.Phase 3 Recruiting202 enrolled